Toshifumi Tada

119PUBLICATIONS
144CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (119)

|Aug 07, 2026
Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial".

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

|May 04, 2026
Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models.

Pageof 20

Frequent Collaborators

78 joint publications

Hidenori Toyoda

70 joint publications

Takashi Kumada

63 joint publications

Atsushi Hiraoka

51 joint publications

Takeshi Hatanaka